

PRESS RELEASE

**XERAYA AND MIRXES ANNOUNCES A JOINT VENTURE TO ESTABLISH
MYRNA DIAGNOSTICS SDN. BHD.**

6 OCTOBER 2025

Xeraya Capital via Xeraya Opportunities Fund PCC Limited (“**Xeraya**”) and Mirxes International Holding Limited (“**Mirxes**”), a wholly-owned subsidiary of Mirxes Holding Company Limited entered into a joint venture agreement to establish MyRNA Diagnostics Sdn. Bhd. (“**MyRNA**”). The shareholding structure of MyRNA consists of 60% held by Xeraya and 40% held by Mirxes. The purpose of MyRNA shall be to conduct research, development, commercialization, and obtain regulatory approval for cancer early detection and other nucleic acid-based tests in Malaysia.

Malaysia, a dynamic upper-middle-income economy with a population of around 35 million people, is facing an escalating cancer burden, with approximately 51,650 new cancer cases and 31,633 deaths recorded in 2022 (Global Cancer Observatory, 2022). Notably, over 60% of cancers in Malaysia are diagnosed at late stages (Stage III or IV), severely limiting survival outcomes and placing strain on the national healthcare system (National Strategic Plan for Cancer Control Programme, 2021–2025). With Malaysia’s cancer incidence estimated to increase by more than 70% by 2050 (Global Cancer Observatory, 2022), early detection remains an urgent critical unmet need, especially for high-incidence cancers such as lung, colorectal, breast, liver and gastric cancers, which collectively account for nearly 50% of all cases.

Through the strategic joint venture with Mirxes, a leading innovator in early cancer detection with a state-of-the-art miRNA centric, multi omic technology platform and proven blood-based cancer tests, Xeraya seeks to:

- i. support the establishment of Malaysia’s leading early cancer detection platform, addressing the nation’s critical unmet needs in early detection and precision medicine;
- ii. anchor a strong and localized specialty early cancer testing operation in Malaysia,
 - a. scaling Mirxes’ existing clinical business through localized testing services to enhance turnaround time and cost-efficiency for customers;
 - b. enabling faster engagement and entry into new market segments, including public healthcare institutions;
- iii. leverage Malaysia’s robust biotechnology and healthcare ecosystem to accelerate development of Mirxes’ clinical pipeline through MyRNA, including colorectal, breast, liver, and multi cancer tests;

- iv. foster cross-border synergies across Mirxes' R&D and clinical operations in Singapore, China, and Malaysia, to expedite regulatory approvals of *in vitro* diagnostics (IVDs) and the deployment of innovative lab-developed tests (LDTs); and
- v. build a scalable regional platform, positioning Malaysia as a launchpad for expansion into ASEAN and other markets with similar epidemiological profiles, genetic backgrounds, and unmet screening needs.

The establishment of MyRNA is expected to deliver significant healthcare, economic, and innovation impact for Malaysia. By enabling early detection of cancers, MyRNA will improve survival outcomes while reducing the long-term cost burden on the healthcare system, estimated at RM1.34 billion annually. The platform's scalable diagnostics will expand access to wider populations, particularly beyond the Klang Valley, addressing healthcare equity across the nation.

In addition, the initiative is expected to contribute to the creation of up to 15 high-skilled knowledge-worker positions (with an average salary of >RM4,000) over the next five years. With strong potential for technology transfer and local manufacturing, MyRNA will also help reduce reliance on imports and bolster Malaysia's biotech value chain. Importantly, the initiative aligns directly with the Ministry of Health's Health White Paper (2023–2030), strengthening preventive care, expanding accessibility, and driving industry growth through R&D and clinical trials. MyRNA will also look to strengthen its R&D program with local universities and research institutions with further strengthening of the national cancer registries with clinical trials conducted in Malaysia.

For further information please contact:-

Ms Adha Roslan

Corporate Communications & Investor Relations

Xeraya Capital

Tel: +6011 2607 3220